A real-world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation. (PubMed, Br J Haematol) - Jul 13, 2026 - "Compared with the 200-day group, the 100-day group had more late CMV reactivation after discontinuation during follow-up (21.6% vs. 0%; p < 0.001) and numerically lower 1-year overall survival (80.4% [95% confidence interval (CI), 66.6-88.9] vs. 93.5% [95% CI, 81.1-97.8]; log-rank p = 0.103), without more severe chronic graft-versus-host disease or grade ≥3 drug-related adverse events. These real-world findings suggest that both earlier initiation and longer letermovir prophylaxis deserve further evaluation after allo-HSCT."
Journal • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Transplantation
|
|
Shiyu Chen; Xiaohan Zhang; Xiaoqing Li; Xin Du; Zhihang Su
|